Guides Guides
The Pre-GLP-1 Blueprint: Establishing Metabolic, Hormonal, and Medication Safety Before Treatment
Written by SiPhox Health Research Team
Last updated: May 6, 2026
5 mins read
What is Pre-GLP-1 baseline testing?
Pre-GLP-1 baseline testing is a structured health assessment performed before starting GLP-1 receptor agonist medications (such as semaglutide, liraglutide, or tirzepatide).
Its purpose is to establish a true cardiometabolic and clinical reference point before treatment begins, allowing for accurate interpretation of metabolic changes over time.
This includes identifying underlying issues such as:
- Thyroid dysfunction
- Lipid abnormalities
- Testosterone imbalance
- Early fatty liver disease (NAFLD)
- Insulin resistance patterns
Without a baseline, it becomes difficult to distinguish medication effects from pre-existing metabolic or pharmacological influences.
Why a baseline matters before starting GLP-1 therapy
GLP-1 medications can significantly affect:
- Weight and appetite regulation
- Glucose metabolism
- Lipid profiles
- Liver fat content
- Gastrointestinal function and drug absorption
Because these changes can occur rapidly, starting therapy without baseline data reduces interpretability of outcomes.
A structured baseline helps:
- Identify pre-existing metabolic risk
- Detect hidden endocrine or lipid abnormalities
- Establish a clear comparison point for treatment response
- Improve long-term safety and tracking accuracy
What should be assessed before starting GLP-1s?
A comprehensive Pre-GLP-1 baseline focuses on cardiometabolic, endocrine, and pharmacological safety factors:
1. Thyroid function
Thyroid hormones regulate metabolic rate and energy balance. Undiagnosed dysfunction can influence weight response and symptom interpretation.
2. Lipid profile
Elevated triglycerides and dyslipidemia are key metabolic risk factors and relevant for overall cardiometabolic health and pancreatitis risk stratification.
3. Liver health (NAFLD risk)
Non-alcoholic fatty liver disease is closely linked to insulin resistance and may improve significantly with GLP-1 therapy.
4. Sex hormones
Hormonal imbalance can affect fat distribution, energy levels, and metabolic adaptation.
5. Glycemic and insulin markers
These define baseline insulin resistance and expected metabolic response trajectory.
6. Reproductive and pregnancy status
Pregnancy status must be assessed before starting GLP-1 therapy, as these medications are not recommended during pregnancy due to insufficient human safety data and potential fetal risk.
7. Current Medications and Interaction Risk
Before starting GLP-1 receptor agonist therapy, you should inform their clinician of all medications they are taking, including prescription drugs, over-the-counter treatments, and supplements. This is important because GLP-1 medications slow gastric emptying and intestinal transit, which can affect how other drugs are absorbed and tolerated.
Special attention should be paid to the following categories:
- Medications with narrow therapeutic windows (where small changes in blood levels can have significant effects)
Examples: warfarin, levothyroxine, lithium
- Medications requiring consistent absorption or timing (where altered absorption may reduce efficacy or stability)
Examples: levothyroxine, oral contraceptives, tacrolimus
- Diabetes medications that increase hypoglycemia risk when combined
Examples: insulin, sulfonylureas such as glipizide or gliclazide
- Medications that affect gastrointestinal motility or are affected by it
Examples: metoclopramide, loperamide, erythromycin
- Patients on complex polypharmacy or unstable regimens (e.g., multiple cardiovascular, psychiatric, or endocrine medications with frequent dose adjustments)
Examples: antidepressants (sertraline, amitriptyline), antiepileptics (valproate, carbamazepine), antihypertensives (amlodipine, beta-blockers such as bisoprolol)
Because GLP-1 therapy can slow digestion, it may alter the timing, absorption, and overall effectiveness of co-administered medications, particularly during dose initiation and escalation. Careful monitoring and individualized dose adjustments may therefore be required under medical supervision.
When NOT to start GLP-1 medications
GLP-1 therapy should be avoided or delayed in the presence of certain clinical conditions.
You should be made aware of these risks and inform your physician if you have any of the following conditions before starting GLP-1 treatment:
- Active or suspected pancreatitis
- Previous history of pancreatitis
- Unexplained persistent or severe abdominal symptoms
- Untreated or symptomatic gallbladder disease
- Previous history of gallbladder disease
- Severe gastrointestinal disorders affecting gastric emptying
- Uncontrolled endocrine disorders requiring stabilization
-
Pregnancy or active attempts to conceive without medical supervision
GLP-1 receptor agonists are not recommended during pregnancy. Treatment should be avoided or discontinued if pregnancy occurs, with appropriate clinical follow-up.
- History of contraindicated thyroid malignancy (e.g., medullary thyroid carcinoma or MEN2)
- Severe malnutrition or eating disorders requiring primary stabilization
- Unstable or high-risk medication regimens where absorption or dosing cannot yet be safely predicted
In these cases, initiating therapy without addressing underlying risks may reduce safety and clinical clarity.
How baseline and Day 0 testing works
A structured Pre-GLP-1 protocol typically involves two steps:
1. Baseline assessment (pre-screening phase)
- Identifies metabolic, endocrine, reproductive, and medication-related risks
- Establishes eligibility and risk stratification
2. Day 0 (treatment initiation point)
- Re-confirms baseline status immediately before first dose
- Ensures stability of medication and clinical variables
- Locks in reference values for longitudinal tracking
This ensures that all subsequent changes can be attributed to therapy and lifestyle rather than pre-existing variability.
Why this matters clinically
Without structured baseline assessment, GLP-1 response interpretation becomes less precise. For example:
- Weight loss may mask underlying thyroid dysfunction
- Lipid improvements may reflect baseline fluctuation rather than treatment effect
- Gastrointestinal symptoms may be misattributed to medication instead of pre-existing disease or drug interactions
- Medication side effects may be misinterpreted if absorption changes are not accounted for
A structured baseline ensures clarity, safety, and meaningful long-term metabolic insight.
Where can I read more?
GLP-1 analog therapy and hemoglobin levels: Insights from a retrospective study โ PMC